|  | **Interval > 14 days (N=51)** | **Interval ≤ 14 days (N=34)** | **Overall (N=85)** |
| --- | --- | --- | --- |
| **Sex** |  |  |  |
| Female | 20 (39.2%) | 18 (52.9%) | 38 (44.7%) |
| Male | 31 (60.8%) | 16 (47.1%) | 47 (55.3%) |
| **Age at diagnosis** |  |  |  |
| Mean (SD) | 14.2 (3.73) | 14.8 (4.57) | 14.4 (4.07) |
| Median [Q1, Q3] | 13.7 [12.0, 16.4] | 14.9 [11.6, 17.5] | 13.9 [11.9, 17.3] |
| **Treatment Year** |  |  |  |
| Mean (SD) | 2010 (5.61) | 2010 (4.73) | 2010 (5.27) |
| Median [Q1, Q3] | 2010 [2010, 2020] | 2010 [2010, 2020] | 2010 [2010, 2020] |
| **Histologic Subtype** |  |  |  |
| Chondroblastic | 10 (19.6%) | 7 (20.6%) | 17 (20.0%) |
| Osteoblastic | 31 (60.8%) | 20 (58.8%) | 51 (60.0%) |
| Periosteal | 1 (2.0%) | 2 (5.9%) | 3 (3.5%) |
| Other | 9 (17.6%) | 5 (14.7%) | 14 (16.5%) |
| **Tumor Site** |  |  |  |
| Long bone | 47 (92.2%) | 32 (94.1%) | 79 (92.9%) |
| Non-long bone | 4 (7.8%) | 2 (5.9%) | 6 (7.1%) |
| **Location of Tumor** |  |  |  |
| Diaphysis | 4 (7.8%) | 5 (14.7%) | 9 (10.6%) |
| Distal | 20 (39.2%) | 15 (44.1%) | 35 (41.2%) |
| Proximal | 23 (45.1%) | 12 (35.3%) | 35 (41.2%) |
| N/A | 4 (7.8%) | 2 (5.9%) | 6 (7.1%) |
| **Grade** |  |  |  |
| High grade | 50 (98.0%) | 32 (94.1%) | 82 (96.5%) |
| Intermediate grade | 1 (2.0%) | 2 (5.9%) | 3 (3.5%) |
| **Stage** |  |  |  |
| Localized | 44 (86.3%) | 28 (82.4%) | 72 (84.7%) |
| Metastatic | 7 (13.7%) | 6 (17.6%) | 13 (15.3%) |
| **Margins** |  |  |  |
| Negative | 45 (88.2%) | 30 (88.2%) | 75 (88.2%) |
| Positive | 6 (11.8%) | 4 (11.8%) | 10 (11.8%) |
| **Tumor Necrosis** |  |  |  |
| Mean (SD) | 0.686 (0.306) | 0.735 (0.256) | 0.705 (0.286) |
| Median [Q1, Q3] | 0.800 [0.500, 0.950] | 0.825 [0.585, 0.973] | 0.800 [0.500, 0.950] |